Alendronate — A new bisphosphonate
Managing Patients With Osteoporosis
- 20 Downloads
Conclusions
These results confirm that alendronate is a potent inhibitor of bone resorption which exerts beneficial effects in postmenopausal women with osteoporosis. It must be borne in mind that the current results relate to clinical trials in ‘ideal’ patients and experience still needs to be gained in treating patients with multiple coexisting problems, who are perhaps more representative of the average patient with osteoporosis. Nonetheless, on the evidence available, alendronate appears to be a promising new addition to the therapeutic armamentarium for osteoporosis.
Keywords
Public Health Clinical Trial Osteoporosis Beneficial Effect Postmenopausal Woman
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Allen C, Merck Sharp & Dohme Ltd., personal communication, 1996.Google Scholar
- 2.Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple doses on bone mass and bone remodelling. Am J Med 1995;99:144–52.Google Scholar
- 3.Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–43.Google Scholar
- 4.Weinstein RS, Bone H, Tucci J, Downs R, Harris S, Licata A, et al. Alendronate treatment of osteoporosis in elderly women (abstract). J Bone Miner Res 1994; 9(Suppl 1):S144.Google Scholar
- 5.Howard T, Kimmel D, Recker R, Bone H, Bankhurst A, Barrett J, et al. Minieralization and turnover of bone in elderly women with osteoporosis treated with oral alendronate (abstract). J Bone Miner Res 1995; 1 (Suppl 1):S197.Google Scholar
- 6.Arlot MC, Meunier PJ, Chavassieux P, Recker R, Reda C, Wei L, et al. Effects of long term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry (abstract). J Bone Miner Res 1995; 10(Suppl 1):S199.Google Scholar
- 7.Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693–700.Google Scholar
Copyright information
© European Foundation for Osteoporosis 1996